Replies to post #2322 on Synaptogenix Inc (SNPX)

[SF Wolf]

I agree burg, I would think that Dr. Alkon has had, by now, a number of anecdotal reports about the Ph2b study and that is reflected in the tone and conviction of his presentation.

The company is looking ahead at spending money on a continuation open label Ph2b study, a Ph3 study, and a Fragile X study. Not the type of planning you would expect if the signs were not good.

[xIdXd]

He's the president of the company. Of course he's planning ahead and being optimistic about results.

It's like saying you're expecting great results from Sears because Edward Lampert told stockholders he was optimistic about future sales.

Take a look behind the curtains though and you'll find that Neurotrope directors just issued 70,000 options to themselves at $19.1 per share, which is barely above today's price.

Now, if the directors were expecting a positive result, why wouldn't they set the option price higher?

Also, NASDAQ still hasn't given its approval, even though the 10-K was released almost 2 weeks ago.

As always, I recommend you look at the data and actual facts instead of anecdotes and predictions.

After all, you can't get sued for misleading stockholders if you hint towards a certain result instead of saying it directly.